The odds ratio for exposure to L-dopa in the IPD patients with PN was 12.4 (95% confidence interval, 1.4–109.1). There were no differences between the groups in the use of other PD drugs ...
L-DOPA (L-3,4-dihydroxyphenylalanine) remains the most effective drug for the treatment of Parkinson's disease. However, chronic use causes dyskinesia, a complex motor phenomenon that consists of ...
Previous studies in a rat model of Parkinson disease (PD) have shown that dyskinesia induced by L-DOPA—a treatment-limiting adverse effect of long-term administration—is caused by the release ...
Parkinson’s drug comes to market with help of renowned University of Kansas pharmaceutical chemist
Valentino Stella served as a consultant in developing Vyalev, which is delivered subcutaneously to Parkinson’s patients through a wearable pump that’s smaller, more comfortable and effective at ...
NLX-101 (F15599) is under development for the treatment of Rett syndrome and depression. The drug candidate is administered by oral route. The drug candidate is a new chemical entity (NCE). The drug ...
However, nicotine may modulate dopamine transmission and has clear motor effects when associated with L-DOPA, reducing L-DOPA-induced dyskinesias. Clinical trials have yielded inconclusive results ...
Mavoglurant is under development for the treatment of cocaine use disorder, alcohol use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback